A phase III randomised, double-blind trial of immunotherapy with a polyvalent melanoma vaccine (C-VAX) plus bacille Calmette-Guerin (BCG) versus placebo plus BCG as a post surgical treatment for stage IV melanoma

Phase 3

Completed

• Conditions: Stage IV melanoma; Cancer; Malignant neoplasm of skin

• Registration Number: ISRCTN72807124
• Lead Sponsor: Department of Health (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2003-08-01
• Study Start: 2003-09-12
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients with resected stage IV melanoma.

Exclusion Criteria

Does not match inclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progression free survival.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration